LGND enters the final stretch of September with a rare combination: short interest climbing sharply over the past month while the stock itself adds nearly 8% on the week to $298.50 — a tension that sets up the bull-versus-bear debate in unusually sharp relief.
The positioning story is where the most interesting friction sits. Short interest has risen 33% over the past month to 13.5% of the free float — a high absolute level for a pharma royalty name — yet the lending market is far from panicked. Availability runs near 196%, meaning roughly two shares remain available to borrow for every one already lent out, and cost to borrow is a negligible 0.55%. That combination suggests the short book is building on conviction, not being squeezed out. The ORTEX short score has drifted higher all week, hitting 71.6 on Tuesday — its highest reading in the 30-day window — confirming bears are adding rather than covering. Options traders, however, read the situation differently. The put/call ratio has fallen to 0.0515, the lowest level in a full year, and nearly 1.5 standard deviations below its 20-day average. Calls are dominating activity by an unusual margin, which points to options traders positioning for further upside rather than hedging downside.
The Street is firmly in the bull camp, which helps explain the options skew. Citigroup's Yigal Nochomovitz lifted his target to $397 from $390 just today — the most recent move in what has been a sustained wave of upward revisions. Leerink Partners initiated at Outperform in August, and RBC and BofA Securities both raised targets sharply over the summer, with BofA moving from $266 to $388 in July. The consensus mean target now sits at $343, implying about 15% upside from current levels — a plausible gap, not a stretch. Bulls point to LGND's diversified royalty model and strong royalty revenue momentum; bears flag concentration risk around a limited set of commercial assets and Captisol dependency. EPS momentum factor scores rank in the 68th-75th percentile across 30- and 90-day windows, and the trailing PE of around 26.6x has expanded modestly over the past month — the market is paying more for the earnings stream than it was 30 days ago.
Insider activity over the past 90 days skews negative in aggregate — net selling of roughly $18.3 million across 63,585 shares — though the texture matters. The CLO's sales in early September were all conducted under a pre-arranged 10b5-1 plan, which reduces their signal value considerably. A Director sold 1,200 shares on September 10 without a plan in place, a more discretionary move, but at $342,000 it is not a large enough transaction to carry much weight on its own. On the institutional side, BlackRock holds 15.6% of shares and added 139,000 shares in its most recent filing. Invesco added nearly 370,000 shares. Both filings are passive 13G positions with no activist intent, but the direction of travel — major index managers adding into strength — is consistent with the bullish price action.
LGND reports Q3 results on November 6. The last two prints produced modest post-release declines — down 1.5% on the day after August 2026 results and down 3.1% after the prior print, with losses extending to roughly 2-4% over the subsequent five sessions. With short interest near 13.5% of float and still building, and the stock up over 57% year-to-date, the next earnings catalyst becomes the key test of whether bears cover or dig in further — and whether the options market's unusual call-side dominance proves prescient.
See the live data behind this article on ORTEX.
Open LGND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
